Evonile Pharma Reports Q2 FY27 Results with Exceptional Loss
Novartis India Ltd · Financial Result · 04 Nov 2026, 12:53 am
Evonile Pharma Reports Q2 FY27 Results with Exceptional Loss Evonile Pharma posted a net loss of ₹775.4m for the quarter ended 30th Sep'26, down from a net profit of ₹242.2m YoY and ₹322.1m QoQ. Revenue from operations dropped 37.95% YoY to ₹560.5m. The performance was severely impacted by an exceptional item of ₹682.6m, primarily relating to ₹610.0m from the termination of distribution arrangements with a major customer. Additionally, the company acquired trademark assets for ₹12,900.0m and approved raising up to ₹9,000.0m via a rights issue.
Original exchange filing (PDF)
More announcements from Novartis India Ltd
- Transcript of the Earnings Call held on Wednesday, November 04, 2026. · 06 Nov 2026
- Submission of the Letter of Offer in connection with the proposed Rights Issue of the Partly Paid-up Equity Shares of the Company. · 06 Nov 2026
- Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026. · 05 Nov 2026
- Outcome of the Board Meeting held today i.e. November 04, 2026 · 05 Nov 2026
- Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 2026 · 05 Nov 2026
- Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026. · 04 Nov 2026
- Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
